Primary effusion lymphoma
Clinical trials for Primary effusion lymphoma explained in plain language.
Never miss a new study
Get alerted when new Primary effusion lymphoma trials appear
Sign up with your email to follow new studies for Primary effusion lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug combo tame a rare, untreated lymphoma?
Disease control OngoingThis trial tests whether adding lenalidomide to a standard chemotherapy regimen (DA-EPOCH) plus rituximab can help people with primary effusion lymphoma, a rare and aggressive cancer linked to the KSHV virus. The study includes adults aged 18 and older with this disease, regardle…
Matched conditions: PRIMARY EFFUSION LYMPHOMA
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Matched conditions: PRIMARY EFFUSION LYMPHOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Hidden bone loss: HIV and cancer patients under the scanner
Knowledge-focused OngoingThis study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…
Matched conditions: PRIMARY EFFUSION LYMPHOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC